Clinical Trials Market Size To Reach $158.4 Billion By 2033

April 2026 | Report Format: Electronic (PDF)

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 158.4 billion by 2033, registering a CAGR of 7.7% from 2026 to 2033, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug.

The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.

The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.

key Request a free sample copy or view report summary: Clinical Trials Market Report

Clinical Trials Market Report Highlights

Based on phase, the phase III segment led the market, accounting for a revenue share of 53.6% in 2025. Phase III trials are the most expensive and involve a large number of subjects. The median cost for a single-phase III trial is over USD 19.0 million.
Based on study design, the interventional studies segment dominated the clinical trials market in 2025. It is one of the most widely used methods in clinical trials. Interventional studies accounted for over 75.0% of the total registered studies in 2022, of which most were drug or biologics, followed by clinical procedures, behavioral, and device interventional studies. Based on indication, oncology segment accounted for largest market revenue share in 2024.
Based on indication, the oncology segment accounted for the largest revenue share of the clinical trials industry in 2025. According to the U.S. FDA and other sources, the pharmaceutical industry currently spends more than USD 38.0 billion on the preclinical and clinical development of oncology therapy products.
Based on service, the laboratory services segment garnered significant market share in 2025. The growing complexity of clinical trials, coupled with the adoption of biomarker-based research, has created a need for high-quality diagnostic and analytical laboratories at all stages.
Based on sponsor, pharmaceutical & biopharmaceutical companies accounted for the largest revenue share of the clinical trials industry in 2025. This can be attributed to the greater interest of the pharmaceutical industry in the research field.
North America accounted for 50.7% of the global clinical trials industry in 2025 and is expected to continue its dominance over the forecast period. This can be attributed to increased R&D investments and the adoption of new technologies in clinical trials in this region.

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, indication by study design, service, sponsor, and region:

Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I
Phase II
Phase III
Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional Trials
Observational Trials
Expanded Access Trials

Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome (IBS)
- Others
Pain Management
- Chronic Pain
- Acute Pain
Oncology
- Blood Cancer
- Solid Tumors
- Others
CNS Conditions
- Epilepsy
- Parkinson's Disease (PD)
- Huntington's Disease
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle Regeneration
- Others
Diabetes
Obesity
Cardiovascular Diseases
Others

Clinical Trials Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Pain Management
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Oncology
- Interventional Trials
- Observational Trials
- Expanded Access Trials
CNS Conditions
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Diabetes
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Obesity
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Cardiovascular Diseases
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Others
- Interventional Trials
- Observational Trials
- Expanded Access Trials

Clinical Trials Service Outlook (Revenue, USD Million, 2021 - 2033)

Protocol Designing
Site Identification
Patient Recruitment
Laboratory Services
Analytical Testing Services
Clinical Trial Data Management Services
Others

Clinical Trials Sponsor Outlook (Revenue, USD Million, 2021 - 2033)

Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others

Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- India
- China
- Japan
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
- Columbia
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman